Novartis (NVS Quick QuoteNVS - Free Report) reported $13.11 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 0.9%. EPS of $1.99 for the same period compares to $2.28 a year ago.

The reported revenue represents a surprise of -3.31% over the Zacks Consensus Estimate of $13.56 billion. With the consensus EPS estimate being $2.11, the EPS surprise was -5.58%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Oncology- Tasigna- US: $28 million versus $39.24 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -85.8% change.
• Net sales- Oncology- Scemblix- ROW: $147 million compared to the $159.85 million average estimate based on three analysts.
• Revenues- Oncology- Promacta/Revolade- US: $25 million versus the three-analyst average estimate of $58.23 million. The reported number represents a year-over-year change of -91.3%.
• Revenues- Immunology- Cosentyx- US: $770 million compared to the $891.17 million average estimate based on three analysts. The reported number represents a change of -5.5% year over year.
• Revenues- Oncology- Tafinlar + Mekinist- Total: $493 million versus $555.25 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.7% change.
• Revenues- Net sales to third parties: $13.11 billion compared to the $13.56 billion average estimate based on three analysts. The reported number represents a change of -0.9% year over year.
• Revenues- Oncology- Kisqali- Total: $1.52 billion compared to the $1.47 billion average estimate based on three analysts. The reported number represents a change of +58.6% year over year.
• Revenues- Immunology- Cosentyx- Total: $1.57 billion versus the three-analyst average estimate of $1.65 billion. The reported number represents a year-over-year change of +2.1%.
• Revenues- Cardiovascular- Entresto- Total: $1.31 billion versus the three-analyst average estimate of $1.42 billion. The reported number represents a year-over-year change of -42.3%.
• Revenues- Established Brands- Exforge Group- Total: $203 million versus the three-analyst average estimate of $188.4 million. The reported number represents a year-over-year change of +13.4%.
• Revenues- Established brands- Kymriah- Total: $81 million versus the three-analyst average estimate of $90.21 million. The reported number represents a year-over-year change of -19%.
• Revenues- Oncology- Tasigna- Total: $155 million versus the three-analyst average estimate of $160.94 million. The reported number represents a year-over-year change of -58.9%.

View all Key Company Metrics for Novartis here>>>

Shares of Novartis have returned -4.1% over the past month versus the Zacks S&P 500 composite's +12.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.